Cathie Wood’s ARK Genomic Revolution EFT has made big investments in the psychedelics sector since February 2022, specifically in Atai Life Sciences ATAI. The fund has now gone lower and released one extensive report Exploring “the therapeutic virtues” and what the industry is investment prospects look.

Written by a research associate Pierce JamiesonARCs “How Far Away Are Psychedelic Therapeutics?” agrees with similar analyses KPMG and MorganStanley. Together they certainly weigh something retail investor Those new to the sector might consider a pretty good looking market to get exposure to.

That piece takes the reader through a brief introduction to the history of psychedelic substances and then moves on to a scientific overview of eight related compounds and their current clinical status. It is then examined which investments harbor risks and which opportunities in the industry.

The published information includes average values litigation costs, Average Time span for drug development and approval, Market Size Forecast (Adoption by practitioners, patients, sale) and further offers a Comparison between estimated prices of future treatment options.

For example, ARK estimates that by 2022 in the US alone, the cumulative economic burden associated with major depressive disorder (MDD), opioid use disorder (OUD), and post-traumatic stress disorder (PTSD) collectively total approximately $1.4 trillion per year, with direct healthcare costs of approximately $270 billion.

Given these numbersthe fund evaluates the annual drug associated sales opportunity with these figures for 2022 in the USA $44 billion or ~3.1% of total economic liability.

Within the potential options available for treating these conditions, the data collected and analyzed suggests that psilocybin is suitable Advantages in durability, safety and effectiveness while at the same time reducing the costs for the healthcare system.

That Total number of forecasted sales for magic…